NEW YORK, Jan. 21, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) TRDA. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Entrada and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

After the market closed on December 19, 2022, Entrada issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) approved the Company’s investigational new drug application for ENTR-601-44 clinically shelved for the possible treatment of Duchenne muscular dystrophy. The FDA indicated that they would issue an official Clinical Hold Letter to Entrada within 30 days.

As a result of this news, Entrada’s stock price fell $3.93 per share, or 19.76%, to close at $15.96 per share on December 20, 2022.

The Pomerantz law firm, with offices in New York, Chicago, Los Angeles and Paris, is one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as Dean of the Class Attorney’s Association, the Pomerantz firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz law firm continues the tradition he established and fights for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomerantzlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980